Chen Xiaomin, Zheng Tian, Zeng Wen, Fu Xia, Wang Shun, Zeng Weijuan, Ke Min
Department of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
J Ophthalmol. 2021 Jul 7;2021:9938928. doi: 10.1155/2021/9938928. eCollection 2021.
The purpose of this study was to assess the efficacy and safety of intraocular direct cyclophotocoagulation (IDCP) using a 532 nm laser with combination treatment in reducing intraocular pressure (IOP) for patients with advanced neovascular glaucoma (NVG) with angle closure. In addition, we sought to determine the success rate and frequency of complications and explore an optimized solution to reduce the number of topical medications and the pain of patients.
A retrospective case note review of all patients undergoing combined treatment including IVR, phaco, PPV, PRP, and IDCP from January 2017 to June 2018.
In total, 24 consecutive patients (25 eyes) were reviewed. The mean IOP was significantly decreased from 42.2 ± 8.5 mmHg preoperatively to 15.56 ± 2.0 mmHg ( < 0.0001), and no neovascularization of the iris (NVI) reoccurred at month 18. The number of medications used was reduced from 2.72 ± 0.45 preoperatively to 0.87 ± 0.40 at month 18 ( < 0.0001).
During 18 months of follow-up, the combined treatments were safe and had a significant IOP-lowering effect. This study provides a new method of performing IDCP with a 532 nm laser, allowing for the use of internal cyclophotocoagulation without extra equipment.
本研究旨在评估采用532nm激光进行眼内直接睫状体光凝术（IDCP）联合治疗对晚期新生血管性闭角型青光眼（NVG）患者降低眼压（IOP）的疗效和安全性。此外，我们试图确定成功率和并发症发生率，并探索一种优化方案以减少局部用药数量和患者痛苦。
对2017年1月至2018年6月期间所有接受包括玻璃体内注射抗血管内皮生长因子（IVR）、白内障超声乳化吸除术（phaco）、玻璃体切割术（PPV）、视网膜光凝术（PRP）和IDCP在内的联合治疗的患者进行回顾性病例记录审查。
共审查了24例连续患者（25只眼）。平均眼压从术前的42.2±8.5mmHg显著降至18个月时的15.56±2.0mmHg（<0.0001），且在18个月时虹膜新生血管（NVI）未复发。用药数量从术前的2.72±0.45种减少至18个月时的0.87±0.40种（<0.0001）。
在18个月的随访期间，联合治疗安全且具有显著的降眼压效果。本研究提供了一种使用532nm激光进行IDCP的新方法，无需额外设备即可进行眼内睫状体光凝术。
